Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Reuters
Reuters
Business

Eli Lilly, AbCellera Biologics to co-develop coronavirus therapies

FILE PHOTO: The logo and ticker for Eli Lilly and Co. are displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., May 18, 2018. REUTERS/Brendan McDermid

Eli Lilly Co and privately-held AbCellera Biologics Inc on Thursday announced they would co-develop antibody products for the treatment of COVID-19, a flu-like disease caused by the fast-spreading coronavirus.

AbCellera and Lilly have committed to equally share initial development costs towards a product, the companies said.

Lilly will be responsible for all further development, manufacturing and distribution.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Arun Koyyur)

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.